The Sgk1-105, also known as SGK1 (Serum/Glucocorticoid Regulated Kinase 1) inhibitor, is a research chemical that has garnered interest in various scientific studies, particularly in the context of cellular biology and potential therapeutic applications. Developing a comprehensive guide for Sgk1-105 involves understanding its role, applications, and handling procedures.
Based on typical kinase inhibitors:
No direct structural analogs of SGKI-105 are publicly available. Related SGK1 inhibitors from literature include: sgki-105
Metformin is usually started at a low dose (500mg or 850mg) once or twice daily with meals to minimize gastrointestinal side effects. sgki-105
SGK1 in Human Cancer: Emerging Roles and Mechanisms - PMC - NIH sgki-105
It limits the amount of sugar the liver produces and releases into the bloodstream.